IP Library Granted Patent US 9,651,541
Granted Patent B2
US 9,651,541 · App. 14/062,745 · Granted May 16, 2017

Acidic solid oral compositions without erosive potential in saliva and method for determining erosive potential in saliva

Inventors: Thorbjorg Jensdottir (Vassoy, NO); Allan Bardow Jensen (Naerum, DK); Birgitte Nauntofte (Charlottenlund, DK); Christian Buchwald (Hellerup, DK)
Assignee: Ice Medico ehf
G01N33/50A23G3/34A23G3/36A23G3/362A23G4/06A23G4/064A23G9/32A23G9/325A61K8/0216A61K8/19A61K8/365A61K9/0056A61Q11/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,651,541
App. No.
14/062,745
Granted
May 16, 2017
Kind
B2
Abstract

Acidic oral compositions having calcium contents and effective pH-values in the area indicated by grey-tone in FIG. 2 are non-erosive in saliva and capable of stimulating saliva production, even in “dry mouth” patients. A new multi-step test method for determining erosive potential in saliva has been used for identifying the compositions.

Claims (29)

1. An acidic solid oral composition, which is a boiled sweet, a candy, a lollipop, a jelly, a chewing gum, a drop, a pastille, a lozenge, an ice cream, a sorbet or a tablet, comprising a calcium component and an acid component, wherein the composition stimulates saliva production and is non-erosive to teeth in saliva,

wherein the calcium component is selected from the group consisting of calcium carbonate, calcium hydroxide, calcium citrate, calcium malate, calcium lactate, calcium chloride, calcium glycerophosphate, calcium acetate, calcium sulphate, and calcium formate, or hydrates or combinations thereof,

wherein the acid component is selected from the group consisting of citric add, malic acid, ascorbic acid, tartaric acid, acetic acid, fumaric acid and lactic acid,

wherein amounts of the calcium component and the acid component in the solid oral composition are adjusted so as to provide

(i) a pH in a range of 2.5 to 3.2, when the solid oral composition is dissolved in an equal amount by weight of highly purified water, and

(ii) a calcium content in the acidic solid oral composition within the following limits:

175−(50·pH)≦calcium content (mmol/kg)≦660−(200·pH),

the pH being as indicated above, with the proviso that the solid oral composition does not include a polyphosphate that is a phosphate polymer having a number (n) of phosphate groups wherein the number of phosphate groups (n) is at least 3.

2. A solid composition according to claim 1 , wherein the mole ratio of calcium component to acid component is in the range of 0.3 to 0.8.

3. A solid composition according to claim 2 , wherein the mole ratio of calcium component to acid component is in the range of 0.4 to 0.7.

4. A solid composition according to claim 1 , wherein the pH, determined as indicated in claim 1 , is between 2.6 and 3.1.

5. The solid composition of claim 1 , wherein the calcium component is calcium lactate.

6. A solid composition according to claim 1 , which is intended for being sucked or chewed.

7. A method for stimulating the saliva production in an individual comprising orally administering a solid composition according to claim 1 to the individual.

8. A method according to claim 7 , which is not for treatment of the human or animal body by therapy.

9. A method according to claim 7 , for alleviating the sufferings of an individual having impaired saliva production.

10. A method according to claim 9 , wherein the impaired saliva production is caused by a disease such as Sjögren's syndrome, cystic fibrosis, diabetes or an eating disorder.

11. A method according to claim 9 , wherein the impaired saliva production is caused by a therapeutic treatment, such as a medical treatment or radiotherapy.

12. The solid oral composition of claim 1 , for which, when tested in randomly selected healthy test persons by a method comprising the steps of:

(a) bringing the oral composition to be tested into contact with saliva in the mouth,

(b) collecting a sample of the saliva under conditions so as to prevent CO 2 from escaping from the sample,

(c) measuring pH of the sample collected under (b) to obtain a pH value,

(d) removing CO 2 from the sample collected under (b),

(e) adjusting pH of the sample from which CO 2 has been removed in step (d) to the pH value measured in step (c), by adding a non-volatile acid or a non-volatile base, to obtain a pH-adjusted sample

(f) adding tooth substance to the pH-adjusted sample obtained from step (e), and observing any rise in pH of the pH-adjusted sample,

(g) if a rise in pH is observed in the sample of step (f), titrating the sample to the pH value measured in (c) using an acid to determine an amount of the acid that is consumed, and

(h) calculating an amount of tooth substance eroded based on the amount of acid consumed in step (g),

no rise in pH in step (f) is observed, within a period of 5 minutes for at least 90% of the test persons.

13. The solid oral composition of claim 12 wherein step (d) of removing is assisted by at least one of: (i) vacuum treatment, and (ii) addition of a non-volatile strong acid.

Assignments (4)
WAIVER OF LICENSE AGREEMENT Recorded Aug 8, 2017
From: TOMS GRUPPEN A/S
To: ICEMEDICO EHF
Reel/Frame 043484/0257 →
CHANGE OF NAME Recorded Aug 8, 2017
From: ICE MEDICO EHF
To: ICEMEDICO EHF
Reel/Frame 043573/0640 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 26, 2014
From: TOMS GRUPPEN A/S
To: ICE MEDICO EHF
Reel/Frame 032301/0507 →
LICENSE Recorded Feb 26, 2014
From: ICE MEDICO EHF
To: TOMS GRUPPEN A/S
Reel/Frame 032301/0524 →
Priority Claims (1)
DK 2004 01148 · Jul 23, 2004 · national
Continuity (2)
Continuation 11658380
Related Publication 20140121274A1 · May 1, 2014